Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: A multicenter real-life study

International Journal of Infectious Diseases

Volumn 28, Issue , 2014, Pages 153-159

  Batirel, Ayse ^a   Guclu, Ertugrul ^b   Arslan, Ferhat ^c   Kocak, Funda ^d   Karabay, Oguz ^b   Ozer, Serdar ^a   Turanli, Munevver ^e   Mert, Ali ^c  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b SAKARYA UNIVERSITY   (Turkey)

^c ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^d Basaksehir State Hospital   (Turkey)

^e ISTANBUL COMMERCE UNIVERSITY   (Turkey)

Author keywords

Chronic hepatitis B; Entecavir; HBV; Tenofovir; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PHOSPHATE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS B; HUMAN; HYPOPHOSPHATEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; NAUSEA; PHOSPHATE BLOOD LEVEL; SEROCONVERSION; SEROLOGY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; RETROSPECTIVE STUDY; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TENOFOVIR;

EID: 84949115549     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.09.004     Document Type: Article

References (28)

1. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185. European Association for the Study of the Liver.
2. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., Chen C.J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
3. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
4. Sunbul M., Sugiyama M., Kurbanov F., Leblebicioglu H., Khan A., Elkady A. Specific mutations of basal core promoter are associated with chronic liver disease in hepatitis B virus subgenotype D1 prevalent in Turkey. Microbiol Immunol 2013, 57:122-129.
5. Sonneveld M.J., Hansen B.E., Piratvisuth T., Jia J.D., Zeuzem S., Gane E., et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013, 58:872-880.
6. Calvaruso V., Mazza M., Almasio P.L. Pegylated-interferon-alpha(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf 2011, 10:429-435.
7. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962.
8. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
9. Liaw Y.F., Gane E., Leung N., Zeuzem S., Wang Y., Lai C.L., et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
10. Fung J., Lai C.L., Seto W.K., Yuen M.F. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011, 66:2715-2725.
11. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
12. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008, 2:263-283.
13. Snow-Lampart A., Chappell B., Curtis M., Zhu Y., Myrick F., Schwalder J., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
14. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006, 44:1656-1665.
15. Ceylan B., Yardimci C., Fincanci M., Eren G., Tozalgan U., Muderrisoglu C., et al. Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci 2013, 17:2467-2473.
16. Dogan U.B., Kara B., Gumurdulu Y., Soylu A., Akin M.S. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 2012, 23:247-252.
17. Guzelbulut F., Ovunc A.O., Oetinkaya Z.A., Senates E., Gökden Y., Salturk A.G., et al. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B. Hepatogastroenterology 2012, 59:477-480.
18. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
19. Liaw Y.F. Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013, 33(Suppl 1):111-115.
20. Abu-Amara M., Feld J.J. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?. Semin Liver Dis 2013, 33:157-166.
21. Woo G., Tomlinson G., Nishikawa Y., Kowgier M., Sherman M., Wong D.F K., et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010, 139:1218-1229.
22. Dakin H., Fidler C., Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010, 13:934-945.
23. Miquel M., Nunez O., Trapero-Marugan M., Diaz-Sanchez A., Jimenez M., Arenas J., et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Ann Hepatol 2013, 12:205-212.
24. Myung H.J., Jeong S.H., Kim J.W., Kim H.S., Jang J.H., Lee D.H., et al. [Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B]. Korean J Hepatol 2010, 16:57-65.
25. van Bommel F., de Man R.A., Wedemeyer H., Deterding K., Petersen J., Buggisch P., et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51:73-80.
26. Chang T.T., Lai C.L., Kew Yoon S., Lee S.S., Coelho H.S., Carrilho F.J., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
27. Lee M.H., Lim S.G., Jeon S.J., Kang C.J., Cho Y.J., Kim S.S., et al. [Clinical efficacy of entecavir therapy and factors associated with treatment response in naive chronic hepatitis B patients]. Korean J Hepatol 2009, 15:446-453.
28. Yao G.B., Ren H., Xu D.Z., Zhou X.Q., Jia J.D., Wang Y.M., et al. [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi 2009, 17:881-886.